Table 2.
Treatment Outcomes Over Time
| Median (IQR) | Mepolizumab, n=123 | Benralizumab n=64 | Intergroup Comparisons | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BL | T 1 | p BL to T1 | T2 | p BL to T2 | Baseline | T1 | p BL to T1 | T2 | p BL to T2 | p Delta BL to T1 | p Delta T1 to T2 | p Delta BL to T2 | |
| FEV1% of predicted | 59 (45, 77) | 74 (59, 89) | <0.001 | 74 (58, 92) | <0.001 | 63,5 (47.5, 83) | 78 (59.5, 93) | <0.001 | 72 (59, 93) | 0.003 | 0.661 | 0.137 | 0.022 |
| FVC % of predicted | 80 (69, 94) | 90 (77, 103) | <0.001 | 93 (78, 107) | <0.001 | 81,0 (66.5, 96.5) | 92,5 (78.5, 104.5) | <0.001 | 89 (75, 105) | 0.002 | 0.839 | 0.036 | 0.047 |
| RV % of predicted | 151 (129, 174) | 143 (118, 166) | <0.001 | 133 (113, 159) | <0.001 | 139 (110.5, 162.5) | 131 (114, 160) | 0.57 | 135 (113, 165) | 0.773 | 0.025 | 0.213 | 0.006 |
| TLC % of predicted | 107 (98, 115) | 110 (101, 118) | <0.001 | 108 (98, 118) | 0.823 | 103 (93, 114.5) | 105 (99.5, 115) | 0.191 | 108 (96, 117) | 0.256 | 0.698 | 0.114 | 0.378 |
| ACT score | 13 (9, 17) | 19 (15, 23) | <0.001 | 19 (15, 23) | <0.001 | 12 (9, 16) | 21 (16, 24) | 0.009 | 22 (16, 25) | <0.001 | 0.069 | 0.249 | 0.017 |
| FeNO in ppb | 41 (23,9, 88) | 38 (18.2, 68) | <0.001 | 32 (20, 56) | 0.002* | 41,5 (16, 73.7) | 37 (22.3, 77.6) | 0.371 | 31 (20, 61) | 0.781* | 0.463 | 0.847 | 0.111 |
| Eosinophils per µL | 500 (236.5, 698.5) | 30 (0.1, 71) | 0.013 | 37,5 (7, 77) | <0.001 | 430 (150, 800) | 10 (0, 10) | <0.001 | 10 (6, 13) | <0.001 | 0.463 | 0.678 | 0.607 |
| Exacerbations per year | 2 (0, 6) | NA | NA | 1 (0, 1) | <0.001 | 2 (0, 6) | NA | NA | 1 (0, 1) | <0.001 | NA | NA | 0.825 |
Note: *Wilcoxon test.
Abbreviations: IQR, interquartile range; T1, follow-up timepoint 1 (6 months); T2, follow-up timepoint 2 (12 months); FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity; mL, milliliter; ACT, asthma control test; OCS, oral corticosteroids; FeNO, fractional expiratory nitric oxide; ppb, parts per billion; NA, not applicable.